The FDA has granted orphan-drug designation to Enlivex Therapeutics' Apocell, an experimental drug for graft-versus-host disease. The designation will give the drug seven years of market exclusivity and "significant regulatory easements, which we believe will shorten marketing approval of the drug in the US, reducing costs," Enlivex CEO Alon Moran said.
Enlivex's GVHD drug Apocell wins orphan status from FDA
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|